Brian Corgiat

Q: What is Brian Corgiat email address?

Email Brian Corgiat at brian.corgiat@theralink.com. This email is the most updated Brian Corgiat's email found in 2026.

Q: How to contact Brian Corgiat?

To contact Brian Corgiat send an email to brian.corgiat@theralink.com. (updated on September 02, 2024)

Senior Clinical Research Scientist at Ignite Proteomics | San Francisco, California, United States

About Brian Corgiat

Brian Corgiat is a dedicated Senior Clinical Research Scientist at Ignite Proteomics, where he leverages his extensive experience in clinical environments to drive innovation in cancer diagnostics. With a strong foundation in molecular and cellular biology, Brian has played a pivotal role in developing a CAP/CLIA accredited breast cancer clinical assay, ensuring that it meets the highest standards of regulatory compliance. His expertise in regulatory documentation has been instrumental in managing the investigational device exemption (IDE) submission for a phase II clinical trial assay, a potential in vitro diagnostic (IVD) that is currently under review by the Food and Drug Administration (FDA).

In his role, Brian has successfully managed over 20 clinical research contracts, collaborating with diverse stakeholders including university partners, pharmaceutical companies, and regulatory consultants. His ability to develop study-specific clinical trial documents—such as clinical study protocols and informed consent documents—demonstrates his comprehensive understanding of the clinical research landscape and regulatory requirements.

Brian's technical skills extend beyond regulatory compliance; he is proficient in assay development and analytical methods development, which are critical for advancing clinical research projects. His experience with data analysis and molecular cloning further enhances his capability to contribute to innovative research initiatives. Passionate about improving patient outcomes through scientific advancement, Brian Corgiat continues to be a driving force at Ignite Proteomics, where he is committed to pushing the boundaries of clinical research and diagnostics in oncology.

Brian Corgiat Work